<博士論文>
滑膜肉腫細胞株において DUSP6 の発現抑制を介した ERK1/2 の活性化はパゾパニブ耐性の誘因となる

作成者
指導教員等
本文言語
学位授与年度
学位授与大学
学位
学位種別
出版タイプ
アクセス権
概要 Synovial sarcoma (SS) is a rare high-grade malignant mesenchymal tumour with a relatively poor prognosis despite intensive multimodal therapy. Although pazopanib, a multi-kinase inhibitor, is often used for advanced SS, most cases eventually become resistant to pazopanib. In the present study, we investigated the mechanisms of acquired pazopanib resistance in SS. To examine acquired pazopanib resistance, two SS cell lines, SYO-1 and HS-SY-II, were isolated after multiple selection steps with increasing concentrations of pazopanib. SYO-1 was also used in vivo. Then, pazopanib-resistant clones were investigated to assess potential mechanisms of acquired pazopanib resistance. Stable pazopanib-resistant clones were established and exhibited enhanced cell cycle progression, cell growth with increased ERK1/2 phosphorylation, and higher sensitivity than parental cells to a MEK-inhibitor, trametinib, both in vitro and in vivo. Furthermore, addition of low-dose trametinib partially reversed the pazopanib resistance. In the pazopanib-resistant clones, dual specificity phosphatase 6 (DUSP6) was downregulated. Inhibition of DUSP6 expression in parental HS-SY-II cells partially recapitulated acquired pazopanib resistance. Acquired pazopanib resistance in SS was associated with activation of ERK1/2 through downregulation of DUSP6 expression. Simultaneous treatment with pazopanib and a MEK inhibitor could be a promising strategy to overcome pazopanib resistance in SS.

本文情報を非表示

med3037 pdf 1.23 MB 4 本文
med3037_abstract pdf 119 KB 3 要旨
med3037_review pdf 170 KB 5 審査結果要旨

詳細

レコードID
査読有無
権利関係
関連情報
関連情報
報告番号
学位記番号
授与日(学位/助成/特許)
受理日
部局
登録日 2017.11.02
更新日 2018.01.23

この資料を見た人はこんな資料も見ています